ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER - Patent 3618820

(19)

(11)

EP 3 618 820 A1

(12)

(43)	Date of publication:
	11.03.2020 Bulletin 2020/11

(21)	Application number: 18723339.0

(22)	Date of filing: 25.04.2018

(51)

International Patent Classification (IPC):

A61K 31/138^(2006.01)
A61K 31/506^(2006.01)
A61P 35/04^(2006.01)

A61K 31/4196^(2006.01)
A61K 31/5685^(2006.01)

(86)	International application number:
	PCT/US2018/029289

(87)	International publication number:
	WO 2018/204138 (08.11.2018 Gazette 2018/45)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
	Designated Extension States:
	BA ME
	Designated Validation States:
	KH MA MD TN

(30)

Priority:

02.05.2017 US 201762500068 P

(71)	Applicant: Eli Lilly and Company
	Indianapolis, IN 46285 (US)

(72)	Inventor:
	SMITH, Ian Charles Indianapolis, Indiana 46206-6288 (US)

(74)	Representative: Smith, Andrew George
	Eli Lilly and Company Limited European Patent Operations Lilly Research Centre Erl Wood Manor Windlesham, Surrey GU20 6PH Windlesham, Surrey GU20 6PH (GB)

(54)	ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER